

FCRL6 antibody - middle region

Rabbit Polyclonal Antibody Catalog # AI12431

Product Information

Application WB
Primary Accession Q6DN72

Other Accession NM 001004310, NP 001004310

Reactivity Human
Predicted Human
Host Rabbit
Clonality Polyclonal
Calculated MW 47748

Additional Information

Gene ID 343413

Alias Symbol FLJ16056, FcRH6

Other Names Fc receptor-like protein 6, FcR-like protein 6, FcRL6, Fc receptor homolog 6,

FcRH6, IFGP6, FCRL6, FCRH6

Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium

azide and 2% sucrose.

Reconstitution & Storage Add 50 ul of distilled water. Final anti-FCRL6 antibody concentration is 1

mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at

20°C. Avoid repeat freeze-thaw cycles.

Precautions FCRL6 antibody - middle region is for research use only and not for use in

diagnostic or therapeutic procedures.

Protein Information

Name FCRL6

Synonyms FCRH6

Function Acts as a MHC class II receptor (PubMed: <u>20519654</u>). When stimulated on its


own, does not play a role in cytokine production or the release of cytotoxic granules by NK cells and cytotoxic CD8(+) T cells (PubMed: 17213291, PubMed: 18991291). Does not act as an Fc receptor (PubMed: 18991291).

Cellular Location Cell membrane; Single-pass type I membrane protein

Tissue Location Expressed by cytolytic cells including NK cells, effector and effector-memory

CD8(+) T-cells, and a subset of NKT cells (at protein level) (PubMed:17213291, PubMed:18991291, PubMed:20933011) Also expressed in gamma delta T cells and in a rare subset of effector CD4(+) T-cells (at protein level) (PubMed:18991291). Expressed in spleen, skin, peripheral blood leukocytes, liver, lung, bone marrow, small intestine and placenta (PubMed:20933011). Expression among T- cells is greatly expanded in HIV-1 infected individuals, and includes not only effector and effector-memory CD8(+) T-cells but also populations of CD4(+) T-cells (PubMed:17213291, PubMed:20933011) Expression among CD8(+) T-cells and NK cells is expanded in individuals with chronic lymphocytic leukemia (CLL) but is reduced in PBMCs from patients with acute (AML), chronic myeloid leukemia (CML) and non- Hodgkin's lymphoma (PubMed:18991291, PubMed:20933011). Expression is higher in PBMCs and/or CD3(+) cells of patients with autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia purpura (ITP) (PubMed:20933011). In contrast, expression in CD3(+) cells from patients with lupus anticoagulans (LA) is higher (PubMed:20933011)

Images



WB Suggested Anti-FCRL6 Antibody Titration: 0.2-1 µg/ml Positive Control: OVCAR-3 cell lysate

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.